Novartis's Q3 2026 investor presentation, published October 27, lists 'Farabursen ADPKD – PhIII FPFV' (first patient, first visit) among its key study starts planned for the second half of 2026. Other programs on the same slide are marked as started, but the farabursen entry has no status yet, meaning the first patient had not been dosed by the end of September.
As of late October 2026, the Phase 3 has not appeared on ClinicalTrials.gov or the EU Clinical Trials Information System. Novartis still lists farabursen (CYX082, a miR-17 inhibitor) in its Phase 1 pipeline table, which reflects the completed Phase 1b rather than any setback.
We have heard community reports that recruitment is starting. Nephrology centres often begin identifying candidates before a trial is publicly listed, so those reports may reflect site preparation. We will update the pipeline as soon as a registry entry or company announcement confirms the trial is open.
Farabursen remains the most closely watched drug in the ADPKD pipeline after its Phase 1b, in which kidney growth was effectively halted (0.05% vs 2.58% on placebo).